Gene detection kit used for [beta] receptor antagonist medication, and detection method and application of gene detection kit

Abstract

The invention discloses a gene detection kit used for [beta] receptor antagonist medication, and a detection method and application of the gene detection kit. The detection kit designs specific amplification primers and sequencing primers by aiming at the polymorphism and the CYP2D6 effective copy number of two genes, including CYP2D6C100T and ADRB1G1165C. The kit comprises the following ingredients: amplification reaction liquid, a CYP2D6C100T sequencing primer, an ADRB1G1165C sequencing primer, a CYP2D6 effective copy number sequencing primer and a positive control. The gene detection kit adopts asymmetric multiplex PCR one-tube amplification on CYP2D6(C100T), ADRB1(G1165C and the CYP2D6 effective copy number, a great quantity of biotin-labeled single-strand DNA is generated, in a single-strand amplification process, a CYP2D7-PNA blocking probe blocks binding of a biotin-labeled probe and a pseudogene CYP2D7 so as to prevent the pseudogene from disturbing a sequencing result, the biotin-labeled single-strand DNA carries out binding with streptavidin, after washing is carried out, the sequencing primers and a sequencing raw material are added, pyrophosphoric acid sequencing is carried out, injuries to an amplified fragment by a strong basicity reagent are reduced, sequencing procedures are simplified, and sequencing time is shortened.

Description

technical field [0001] The invention relates to a gene detection kit for beta-receptor antagonist medication and its method and application, belonging to the field of pharmacogenomic detection. Background technique [0002] Among the top 200 best-selling drugs in the world, drugs for the treatment of high blood pressure accounted for 17 kinds. However, clinical individual response differences in drugs for the treatment of hypertension are very common. About 20%-50% of patients receiving drug therapy have poor blood pressure control. The main reason is that drug-related drug-metabolizing enzymes and The recipient has undergone genetic variation. Individual differences in drug efficacy and adverse reactions are common phenomena in the current drug treatment process. Advances in pharmacogenetics and pharmacogenomics have shown that genetic variation in drug-metabolizing enzymes and receptors (targets of drug action) is the main cause of differences in individual drug response...

AI Technical Summary

Problems solved by technology

Conventional pyrosequencing pretreatment operations are complex and time-consuming. Therefore, it is necessary to design and develop a rapid detection pyrosequencing kit that combines asymmetric PCR technology.

Images